Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid de ...

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of treatment with an investigational dual-target small-molecule inhibitor, ...

Additionally, the mean weekly Peak Pruritus Numerical Rating Scale (PP-NRS) score was 2.9, and the mean Eczema Area and Severity Index (EASI) score was 3.4, both suggesting mild disease activity. The ...

Select secondary endpoints evaluated at 36 weeks included: Proportion of patients achieving ≥90% reduction in Bullous Pemphigoid Disease Area Index (BPDAI; scale: 0-360) Proportion of patients with ≥4 ...

度普利尤单抗应答不佳的患者，转换阿布昔替尼 200 mg QD*治疗 12 周 EASI-90 和 PP-NRS 0/1 应答率高达 55% 和 43.6%，实现双重高效获益，同时，以更高标准达成 34.7% 的 EASI-90 + PP-NRS 0/1 复合终点，60.9% 达 DLQI ≥ 4，快速迈向「无痒愈肤」治疗目标[17]。 图 5：度普利尤单抗 ...

Itch, which was assessed with the patient reported Peak Pruritus Numerical Rating Scale score ranging from 0 to 10, remained low with a mean weekly PP-NRS score of 2.9. The mean Eczema Area and ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...